Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Stock Chart & Stats
$50.26
$0.29(0.76%)
At close: 4:00 PM EST
$50.26
$0.29(0.76%)
Day’s Range― - ―
52-Week Range$29.16 - $57.65
Previous CloseN/A
Volume41.90K
Average Volume (3M)585.39K
Market Cap
$2.97B
Enterprise Value-$117.25B
Total Cash (Recent Filing)$281.16M
Total Debt (Recent Filing)$31.42M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 03, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.00
Shares Outstanding57,339,350
10 Day Avg. Volume574,643
30 Day Avg. Volume585,393
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.92
Price to Sales (P/S)3.01
P/FCF Ratio11.64
Enterprise Value/Market Cap-39.47
Enterprise Value/Revenue-172.03
Enterprise Value/Gross Profit-204.08
Enterprise Value/Ebitda-1.96K
Forecast
1Y Price Target
$61.33Price Target Upside22.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)3.55
Revenue Forecast (FY)$867.27M
Bulls Say, Bears Say
Bulls Say
Integration And Cost SynergiesIntegration of the Sage acquisition has materially reduced SG&A expenses, supporting an improved margin outlook and freeing cash for growth investments.
Onapgo Clinical And Commercial ValidationPhysician enthusiasm, favorable real-world data, and positive head-to-head perceptions versus competing infusion therapy signal strong market receptivity and de-risk Onapgo's commercial rollout.
Qelbree Commercial MomentumQelbree is gaining prescription momentum, particularly among adult patients switching from stimulants, which is expanding market share and strengthening organic revenue growth.
Bears Say
Commercial Uptake UncertaintySlower-than-expected commercial uptake for Qelbree and Onapgo could delay revenue progression and undermine investor confidence.
Competitive And Generic RiskThe possibility of earlier-than-expected generic competition presents a material threat to long-term branded product sales and valuation.
Onapgo Supply ConstraintsPersistent supply constraints for Onapgo, acknowledged by management, risk limiting patient access and constraining near-term sales.
Supernus Pharmaceuticals News
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $29.16 and its highest was $57.65 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.97B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 45 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $1.005 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.415.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.39.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 57,339,350 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $1.005 in its last earnings report, beating expectations of $0.59. Following the earnings report the stock price went down -17.351%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.33 (22.03% Upside)
$61.33 (22.03% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 464.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.19%
12-Months-Change
Fundamentals
Return on Equity
-1.86%
Trailing 12-Months
Asset Growth
5.74%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
SUPN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in key products and an optimistic financial outlook overshadowed by significant operating losses and supply constraints for Onapgo. The company is addressing these challenges while maintaining a focus on future growth opportunities.View all SUPN earnings summariesSUPN Stock 12 Month Forecast
Average Price Target
$61.33
▲(22.03% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Perrigo Company
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Alvotech
―
Ownership Overview
4.29% Insiders
31.80% Mutual Funds
24.11% Other Institutional Investors
12.94% Public Companies and
Individual Investors